{
  "ptid_time": "052_S_1346_2009-04-03",
  "img_path": "/data/qiuhui/data/adni/images/052_S_1346/2009-04-03/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 89,341 mm³, 131.9% above the reference mean. With a Z-score of 3.16 (99.9th percentile), this represents profound enlargement; hippocampal volume measures 4,465 mm³, 40.9% below the reference mean. With a Z-score of -3.99 (0.0th percentile), this represents profound atrophy; whole brain volume measures 1,151,650 mm³, 6.7% above the reference mean. With a Z-score of 0.87 (80.8th percentile), this represents normal volume ; entorhinal cortex volume measures 2,415 mm³, 41.1% below the reference mean. With a Z-score of -2.79 (0.3th percentile), this represents significant atrophy; fusiform gyrus volume measures 17,959 mm³, 4.7% below the reference mean. With a Z-score of -0.40 (34.5th percentile), this represents normal volume ; middle temporal gyrus volume measures 21,730 mm³, 1.8% above the reference mean. With a Z-score of 0.16 (56.5th percentile), this represents normal volume . ",
  "text_data": "Age is 74.6 years. Gender is Male. Education: 12 years. MMSE: 29.0. Logical Memory: 1.0. APOEε4 alleles: 1.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The data shows profound hippocampal and entorhinal cortex atrophy, which are hallmark features of Alzheimer's disease (AD), alongside significant ventricular enlargement (indicative of brain atrophy). However, the MMSE score of 29 is within the normal range, suggesting preserved cognitive function despite structural changes. The presence of one APOE4 allele increases AD risk but does not confirm diagnosis alone.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely prodromal AD given biomarker profile)  \n**Confidence:** **Medium** (high confidence in structural AD-like pathology, but cognitive performance is still intact, making MCI more appropriate than dementia at this stage).  \n\n*Note:* This patient may progress to dementia due to the severity of atrophy, but current cognitive scores do not meet dementia criteria. Follow-up with CSF biomarkers (e.g., Aβ42, p-tau) or amyloid PET would strengthen the diagnosis.",
  "timestamp": "2025-07-26T07:46:33.272219"
}